Key clinical point: Patients with psoriatic arthritis (PsA) were more likely to report remission if they perceived an acceptable disease state, psoriasis remission, and a lower impact of PsA on global quality of life.

Major finding: Patient-reported PsA remission was associated with the achievement of 9-question Psoriatic Arthritis Impact of Disease score of ≤4 (odds ratio [OR] 4.58; P < .05), perception of psoriasis remission (OR 4.51; P < .05), and global quality of life score (OR 0.55; P < .001).

Study details: Findings are from a cross-sectional survey by the National Psoriasis Foundation including 834 patients with psoriasis or PsA.

Disclosures: This study did not receive any funding. Several authors declared serving as research or principal investigators, advisors, or consultants for several sources.

Source: Gondo G et al. Demographic and clinical factors associated with patient-reported remission in psoriatic arthritis. Dermatol Ther (Heidelb). 2022;12(8):1885-1895 (Jul 21). Doi: 10.1007/s13555-022-00770-6

Key clinical point: Patients with psoriatic arthritis (PsA) were more likely to report remission if they perceived an acceptable disease state, psoriasis remission, and a lower impact of PsA on global quality of life.

Major finding: Patient-reported PsA remission was associated with the achievement of 9-question Psoriatic Arthritis Impact of Disease score of ≤4 (odds ratio [OR] 4.58; P < .05), perception of psoriasis remission (OR 4.51; P < .05), and global quality of life score (OR 0.55; P < .001).

Study details: Findings are from a cross-sectional survey by the National Psoriasis Foundation including 834 patients with psoriasis or PsA.

Disclosures: This study did not receive any funding. Several authors declared serving as research or principal investigators, advisors, or consultants for several sources.

Source: Gondo G et al. Demographic and clinical factors associated with patient-reported remission in psoriatic arthritis. Dermatol Ther (Heidelb). 2022;12(8):1885-1895 (Jul 21). Doi: 10.1007/s13555-022-00770-6

Key clinical point: Patients with psoriatic arthritis (PsA) were more likely to report remission if they perceived an acceptable disease state, psoriasis remission, and a lower impact of PsA on global quality of life.

Major finding: Patient-reported PsA remission was associated with the achievement of 9-question Psoriatic Arthritis Impact of Disease score of ≤4 (odds ratio [OR] 4.58; P < .05), perception of psoriasis remission (OR 4.51; P < .05), and global quality of life score (OR 0.55; P < .001).

Study details: Findings are from a cross-sectional survey by the National Psoriasis Foundation including 834 patients with psoriasis or PsA.

Disclosures: This study did not receive any funding. Several authors declared serving as research or principal investigators, advisors, or consultants for several sources.

Source: Gondo G et al. Demographic and clinical factors associated with patient-reported remission in psoriatic arthritis. Dermatol Ther (Heidelb). 2022;12(8):1885-1895 (Jul 21). Doi: 10.1007/s13555-022-00770-6

Key clinical point: In patients with psoriatic arthritis (PsA), risankizumab demonstrated long-term (76 weeks) effectiveness in reducing joint symptoms with a favorable safety profile.

Major finding: At week 16, the American College of Rheumatology 20 criteria response rate was significantly higher with 150 mg risankizumab at weeks 0, 4, 8, 12, and 16 (arm 1) or 150 mg risankizumab at weeks 0, 4, and 16 (arm 2) vs placebo (59.5% [pooled arms 1 and 2] vs 35.7%; P  =  .007), which further improved (75.2%) at week 52. Both risankizumab and placebo had a similar safety profile.

Study details: Findings are from a phase 2 study including 185 patients with active PsA and inadequate response or intolerance to standard therapies who were randomly assigned to receive risankizumab or placebo, of which 145 patients entered the 52-week open-label extension study and received 150 mg risankizumab for 36 weeks.

Disclosures: This study was funded by AbbVie and Boehringer Ingelheim. Some authors declared being current or former employees of Boehringer Ingelheim or AbbVie or owning stocks in AbbVie. The other authors reported ties with several sources, including AbbVie and Boehringer Ingelheim.

Source: Mease PJ et al. Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: Results from a 76-week phase 2 randomized trial. Rheumatol Ther. 2022 (Aug 5). Doi: 10.1007/s40744-022-00474-5

Key clinical point: In patients with psoriatic arthritis (PsA), risankizumab demonstrated long-term (76 weeks) effectiveness in reducing joint symptoms with a favorable safety profile.

Major finding: At week 16, the American College of Rheumatology 20 criteria response rate was significantly higher with 150 mg risankizumab at weeks 0, 4, 8, 12, and 16 (arm 1) or 150 mg risankizumab at weeks 0, 4, and 16 (arm 2) vs placebo (59.5% [pooled arms 1 and 2] vs 35.7%; P  =  .007), which further improved (75.2%) at week 52. Both risankizumab and placebo had a similar safety profile.

Study details: Findings are from a phase 2 study including 185 patients with active PsA and inadequate response or intolerance to standard therapies who were randomly assigned to receive risankizumab or placebo, of which 145 patients entered the 52-week open-label extension study and received 150 mg risankizumab for 36 weeks.

Disclosures: This study was funded by AbbVie and Boehringer Ingelheim. Some authors declared being current or former employees of Boehringer Ingelheim or AbbVie or owning stocks in AbbVie. The other authors reported ties with several sources, including AbbVie and Boehringer Ingelheim.

Source: Mease PJ et al. Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: Results from a 76-week phase 2 randomized trial. Rheumatol Ther. 2022 (Aug 5). Doi: 10.1007/s40744-022-00474-5

Key clinical point: In patients with psoriatic arthritis (PsA), risankizumab demonstrated long-term (76 weeks) effectiveness in reducing joint symptoms with a favorable safety profile.

Major finding: At week 16, the American College of Rheumatology 20 criteria response rate was significantly higher with 150 mg risankizumab at weeks 0, 4, 8, 12, and 16 (arm 1) or 150 mg risankizumab at weeks 0, 4, and 16 (arm 2) vs placebo (59.5% [pooled arms 1 and 2] vs 35.7%; P  =  .007), which further improved (75.2%) at week 52. Both risankizumab and placebo had a similar safety profile.

Study details: Findings are from a phase 2 study including 185 patients with active PsA and inadequate response or intolerance to standard therapies who were randomly assigned to receive risankizumab or placebo, of which 145 patients entered the 52-week open-label extension study and received 150 mg risankizumab for 36 weeks.

Disclosures: This study was funded by AbbVie and Boehringer Ingelheim. Some authors declared being current or former employees of Boehringer Ingelheim or AbbVie or owning stocks in AbbVie. The other authors reported ties with several sources, including AbbVie and Boehringer Ingelheim.

Source: Mease PJ et al. Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: Results from a 76-week phase 2 randomized trial. Rheumatol Ther. 2022 (Aug 5). Doi: 10.1007/s40744-022-00474-5

Key clinical point: A dose of 100 mg guselkumab every 4/8 weeks (Q4W/Q8W) improved health-related quality of life (HRQoL) through 52 weeks in patients with psoriatic arthritis (PsA).

Major finding: A significantly higher proportion of patients receiving guselkumab Q4W/Q8W vs placebo reported minimally important differences in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index (56.0%/56.0% vs 43.4%; P < .006) and Visual Analog Scale (EQ-VAS) score (62.8%/63.5% vs 44.4%; P < .0001) at week 24, with >60% of patients reporting improvements at week 52.

Study details: Findings are from an analysis of the phase 3 DISCOVER 2 trial including 738 biologic-naive patients with active PsA and an inadequate response to standard treatments who were randomly assigned to receive 100 mg guselkumab (Q4W/Q8W) or placebo.

Disclosures: This study was supported by Janssen, a subsidiary of Johnson and Johnson. Eight authors declared being employees of one of the subsidiaries of or owning stocks in Johnson and Johnson. The other authors reported ties with several sources.

Source: Curtis JR et al. The effect of guselkumab on general health state in biologic-naïve patients with active psoriatic arthritis through week 52 of the phase 3, randomized, placebo-controlled DISCOVER-2 trial. Adv Ther. 2022 (Aug 10). Doi: 10.1007/s12325-022-02269-0

Key clinical point: A dose of 100 mg guselkumab every 4/8 weeks (Q4W/Q8W) improved health-related quality of life (HRQoL) through 52 weeks in patients with psoriatic arthritis (PsA).

Major finding: A significantly higher proportion of patients receiving guselkumab Q4W/Q8W vs placebo reported minimally important differences in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index (56.0%/56.0% vs 43.4%; P < .006) and Visual Analog Scale (EQ-VAS) score (62.8%/63.5% vs 44.4%; P < .0001) at week 24, with >60% of patients reporting improvements at week 52.

Study details: Findings are from an analysis of the phase 3 DISCOVER 2 trial including 738 biologic-naive patients with active PsA and an inadequate response to standard treatments who were randomly assigned to receive 100 mg guselkumab (Q4W/Q8W) or placebo.

Disclosures: This study was supported by Janssen, a subsidiary of Johnson and Johnson. Eight authors declared being employees of one of the subsidiaries of or owning stocks in Johnson and Johnson. The other authors reported ties with several sources.

Source: Curtis JR et al. The effect of guselkumab on general health state in biologic-naïve patients with active psoriatic arthritis through week 52 of the phase 3, randomized, placebo-controlled DISCOVER-2 trial. Adv Ther. 2022 (Aug 10). Doi: 10.1007/s12325-022-02269-0

Key clinical point: A dose of 100 mg guselkumab every 4/8 weeks (Q4W/Q8W) improved health-related quality of life (HRQoL) through 52 weeks in patients with psoriatic arthritis (PsA).

Major finding: A significantly higher proportion of patients receiving guselkumab Q4W/Q8W vs placebo reported minimally important differences in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index (56.0%/56.0% vs 43.4%; P < .006) and Visual Analog Scale (EQ-VAS) score (62.8%/63.5% vs 44.4%; P < .0001) at week 24, with >60% of patients reporting improvements at week 52.

Study details: Findings are from an analysis of the phase 3 DISCOVER 2 trial including 738 biologic-naive patients with active PsA and an inadequate response to standard treatments who were randomly assigned to receive 100 mg guselkumab (Q4W/Q8W) or placebo.

Disclosures: This study was supported by Janssen, a subsidiary of Johnson and Johnson. Eight authors declared being employees of one of the subsidiaries of or owning stocks in Johnson and Johnson. The other authors reported ties with several sources.

Source: Curtis JR et al. The effect of guselkumab on general health state in biologic-naïve patients with active psoriatic arthritis through week 52 of the phase 3, randomized, placebo-controlled DISCOVER-2 trial. Adv Ther. 2022 (Aug 10). Doi: 10.1007/s12325-022-02269-0

Key clinical point: Patients with psoriatic arthritis (PsA) who received risankizumab vs placebo were more likely to achieve clinically meaningful improvements in patient-reported outcomes (PRO).

Major finding: At week 24, patients receiving risankizumab vs placebo were significantly more likely to report minimal clinically important differences (MCID) in Patient’s Global Assessment of Disease Activity (PtGA) in both KEEPsAKE-1 (odds ratio [OR] 2.0; P < .001) and KEEPsAKE-2 (OR 1.9; P < .01) studies, with further improvement until week 52. Risankizumab significantly improved other PRO like pain, fatigue, quality of life, and physical functioning (P < .05).

Study details: The data come from an analysis of 2 phase 3 trials, KEEPsAKE-1 and KEEPsAKE-2, including adults with PsA and inadequate response or intolerance to disease-modifying antirheumatic drugs or biologics who were randomly assigned to receive risankizumab or placebo for 24 weeks and only risankizumab during weeks 24-52.

Disclosures: This study was funded by AbbVie. Three authors declared being employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.

Source: Kristensen LE et al. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: Results from KEEPsAKE 1 and 2. J Eur Acad Dermatol Venereol. 2022 (Aug 3). Doi: 10.1111/jdv.18475

Key clinical point: Patients with psoriatic arthritis (PsA) who received risankizumab vs placebo were more likely to achieve clinically meaningful improvements in patient-reported outcomes (PRO).

Major finding: At week 24, patients receiving risankizumab vs placebo were significantly more likely to report minimal clinically important differences (MCID) in Patient’s Global Assessment of Disease Activity (PtGA) in both KEEPsAKE-1 (odds ratio [OR] 2.0; P < .001) and KEEPsAKE-2 (OR 1.9; P < .01) studies, with further improvement until week 52. Risankizumab significantly improved other PRO like pain, fatigue, quality of life, and physical functioning (P < .05).

Study details: The data come from an analysis of 2 phase 3 trials, KEEPsAKE-1 and KEEPsAKE-2, including adults with PsA and inadequate response or intolerance to disease-modifying antirheumatic drugs or biologics who were randomly assigned to receive risankizumab or placebo for 24 weeks and only risankizumab during weeks 24-52.

Disclosures: This study was funded by AbbVie. Three authors declared being employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.

Source: Kristensen LE et al. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: Results from KEEPsAKE 1 and 2. J Eur Acad Dermatol Venereol. 2022 (Aug 3). Doi: 10.1111/jdv.18475

Key clinical point: Patients with psoriatic arthritis (PsA) who received risankizumab vs placebo were more likely to achieve clinically meaningful improvements in patient-reported outcomes (PRO).

Major finding: At week 24, patients receiving risankizumab vs placebo were significantly more likely to report minimal clinically important differences (MCID) in Patient’s Global Assessment of Disease Activity (PtGA) in both KEEPsAKE-1 (odds ratio [OR] 2.0; P < .001) and KEEPsAKE-2 (OR 1.9; P < .01) studies, with further improvement until week 52. Risankizumab significantly improved other PRO like pain, fatigue, quality of life, and physical functioning (P < .05).

Study details: The data come from an analysis of 2 phase 3 trials, KEEPsAKE-1 and KEEPsAKE-2, including adults with PsA and inadequate response or intolerance to disease-modifying antirheumatic drugs or biologics who were randomly assigned to receive risankizumab or placebo for 24 weeks and only risankizumab during weeks 24-52.

Disclosures: This study was funded by AbbVie. Three authors declared being employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.

Source: Kristensen LE et al. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: Results from KEEPsAKE 1 and 2. J Eur Acad Dermatol Venereol. 2022 (Aug 3). Doi: 10.1111/jdv.18475

Key clinical point: The presence of nail dystrophy predicted a better treatment response to secukinumab in patients with psoriatic arthritis (PsA) and axial symptoms.

Major finding: Presence vs absence of nail dystrophy was associated with the achievement of significantly better Assessment of SpondyloArthritis International Society 20 response in the 300 mg secukinumab (odds ratio 5.0; 95% CI 1.47-17.19) vs placebo group (interaction alone P  =  .029).

Study details: Findings are from a post hoc analysis of the phase 3b MAXIMISE trial including 473 adult patients with PsA and axial manifestations who were randomly assigned to receive secukinumab (150 or 300 mg) or placebo.

Disclosures: H Marzo-Ortega and LC Coates reported receiving grants from the UK National Institute for Health Research. The other authors reported ties with several sources outside this work.

Source: Baraliakos X et al. Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: A post-hoc analysis of the MAXIMISE trial. RMD Open. 2022;8(2):e002303 (Jul 18). Doi: 10.1136/rmdopen-2022-002303

Key clinical point: The presence of nail dystrophy predicted a better treatment response to secukinumab in patients with psoriatic arthritis (PsA) and axial symptoms.

Major finding: Presence vs absence of nail dystrophy was associated with the achievement of significantly better Assessment of SpondyloArthritis International Society 20 response in the 300 mg secukinumab (odds ratio 5.0; 95% CI 1.47-17.19) vs placebo group (interaction alone P  =  .029).

Study details: Findings are from a post hoc analysis of the phase 3b MAXIMISE trial including 473 adult patients with PsA and axial manifestations who were randomly assigned to receive secukinumab (150 or 300 mg) or placebo.

Disclosures: H Marzo-Ortega and LC Coates reported receiving grants from the UK National Institute for Health Research. The other authors reported ties with several sources outside this work.

Source: Baraliakos X et al. Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: A post-hoc analysis of the MAXIMISE trial. RMD Open. 2022;8(2):e002303 (Jul 18). Doi: 10.1136/rmdopen-2022-002303

Key clinical point: The presence of nail dystrophy predicted a better treatment response to secukinumab in patients with psoriatic arthritis (PsA) and axial symptoms.

Major finding: Presence vs absence of nail dystrophy was associated with the achievement of significantly better Assessment of SpondyloArthritis International Society 20 response in the 300 mg secukinumab (odds ratio 5.0; 95% CI 1.47-17.19) vs placebo group (interaction alone P  =  .029).

Study details: Findings are from a post hoc analysis of the phase 3b MAXIMISE trial including 473 adult patients with PsA and axial manifestations who were randomly assigned to receive secukinumab (150 or 300 mg) or placebo.

Disclosures: H Marzo-Ortega and LC Coates reported receiving grants from the UK National Institute for Health Research. The other authors reported ties with several sources outside this work.

Source: Baraliakos X et al. Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: A post-hoc analysis of the MAXIMISE trial. RMD Open. 2022;8(2):e002303 (Jul 18). Doi: 10.1136/rmdopen-2022-002303

Key clinical point: The presence of dactylitis and nail disease were associated with improved outcomes in patients with early psoriatic arthritis (PsA) who received etanercept or methotrexate.

Major finding: The presence of both dactylitis and nail disease at baseline were significantly associated with the achievement of minimal disease activity (DA; odds ratio [OR] 1.4; P  =  .0457, and OR 1.8; P  =  .0233, respectively), PsA DA Score (PASDAS) of  low DA (OR 1.8; P  =  .0014, and OR 1.8; P  =  .0168, respectively) responses, and greater reductions in PASDAS scores at week 24 (estimate –3.8; P  =  .0155, and estimate –0.7; P  =  .0005, respectively).

Study details: Findings are from a post hoc analysis of the phase 3 SEAM-PsA trial including 851 biologic/methotrexate-naive patients with active PsA who were randomly assigned to receive methotrexate monotherapy, etanercept monotherapy, or methotrexate+etanercept combination therapy.

Disclosures: This study was funded by Immunex, a wholly owned subsidiary of Amgen. Three authors declared being employees or owning stocks in Amgen, and the other authors reported ties with several sources, including Amgen.

Source: Helliwell PS et al. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: Comparison of treatment effects in the SEAM-PsA trial. RMD Open. 2022;8(2):e002366 (Jul 21). Doi: 10.1136/rmdopen-2022-002366

Key clinical point: The presence of dactylitis and nail disease were associated with improved outcomes in patients with early psoriatic arthritis (PsA) who received etanercept or methotrexate.

Major finding: The presence of both dactylitis and nail disease at baseline were significantly associated with the achievement of minimal disease activity (DA; odds ratio [OR] 1.4; P  =  .0457, and OR 1.8; P  =  .0233, respectively), PsA DA Score (PASDAS) of  low DA (OR 1.8; P  =  .0014, and OR 1.8; P  =  .0168, respectively) responses, and greater reductions in PASDAS scores at week 24 (estimate –3.8; P  =  .0155, and estimate –0.7; P  =  .0005, respectively).

Study details: Findings are from a post hoc analysis of the phase 3 SEAM-PsA trial including 851 biologic/methotrexate-naive patients with active PsA who were randomly assigned to receive methotrexate monotherapy, etanercept monotherapy, or methotrexate+etanercept combination therapy.

Disclosures: This study was funded by Immunex, a wholly owned subsidiary of Amgen. Three authors declared being employees or owning stocks in Amgen, and the other authors reported ties with several sources, including Amgen.

Source: Helliwell PS et al. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: Comparison of treatment effects in the SEAM-PsA trial. RMD Open. 2022;8(2):e002366 (Jul 21). Doi: 10.1136/rmdopen-2022-002366

Key clinical point: The presence of dactylitis and nail disease were associated with improved outcomes in patients with early psoriatic arthritis (PsA) who received etanercept or methotrexate.

Major finding: The presence of both dactylitis and nail disease at baseline were significantly associated with the achievement of minimal disease activity (DA; odds ratio [OR] 1.4; P  =  .0457, and OR 1.8; P  =  .0233, respectively), PsA DA Score (PASDAS) of  low DA (OR 1.8; P  =  .0014, and OR 1.8; P  =  .0168, respectively) responses, and greater reductions in PASDAS scores at week 24 (estimate –3.8; P  =  .0155, and estimate –0.7; P  =  .0005, respectively).

Study details: Findings are from a post hoc analysis of the phase 3 SEAM-PsA trial including 851 biologic/methotrexate-naive patients with active PsA who were randomly assigned to receive methotrexate monotherapy, etanercept monotherapy, or methotrexate+etanercept combination therapy.

Disclosures: This study was funded by Immunex, a wholly owned subsidiary of Amgen. Three authors declared being employees or owning stocks in Amgen, and the other authors reported ties with several sources, including Amgen.

Source: Helliwell PS et al. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: Comparison of treatment effects in the SEAM-PsA trial. RMD Open. 2022;8(2):e002366 (Jul 21). Doi: 10.1136/rmdopen-2022-002366

Key clinical point: Golimumab was effective as a second-line anti-tumor necrosis factor-alpha (TNFα) treatment in a real-world setting of patients with psoriatic arthritis (PsA) who failed the first-line anti-TNFα therapy.

Major finding: After 6 months, 31.9% (95% CI 21.4%–44.0%) and 73.8% (95% CI 58.0%–86.1%) of patients with PsA achieved minimal disease activity and a good/moderate response as per the European Alliance of Associations for Rheumatology, respectively, along with significant improvements in disease activity score in 28 joints based on C-reactive protein score (P < .001).

Study details: Findings are from the prospective, observational, real-world study including 194 patients with moderate-to-active rheumatoid arthritis (n = 39), PsA (n = 91), or axial spondyloarthritis (n = 64) who started golimumab after first-line anti-TNFα inhibitor failure.

Disclosures: This study was funded by MSD Italia S.r.l. Two authors declared being employees of MSD Italia, and the other authors reported ties with several sources, including Merck.

Source: D’Angelo S et al. Effectiveness of golimumab as second anti-TNFα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study. J Clin Med. 2022;11(14):4178 (Jul 19). Doi: 10.3390/jcm11144178

Key clinical point: Golimumab was effective as a second-line anti-tumor necrosis factor-alpha (TNFα) treatment in a real-world setting of patients with psoriatic arthritis (PsA) who failed the first-line anti-TNFα therapy.

Major finding: After 6 months, 31.9% (95% CI 21.4%–44.0%) and 73.8% (95% CI 58.0%–86.1%) of patients with PsA achieved minimal disease activity and a good/moderate response as per the European Alliance of Associations for Rheumatology, respectively, along with significant improvements in disease activity score in 28 joints based on C-reactive protein score (P < .001).

Study details: Findings are from the prospective, observational, real-world study including 194 patients with moderate-to-active rheumatoid arthritis (n = 39), PsA (n = 91), or axial spondyloarthritis (n = 64) who started golimumab after first-line anti-TNFα inhibitor failure.

Disclosures: This study was funded by MSD Italia S.r.l. Two authors declared being employees of MSD Italia, and the other authors reported ties with several sources, including Merck.

Source: D’Angelo S et al. Effectiveness of golimumab as second anti-TNFα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study. J Clin Med. 2022;11(14):4178 (Jul 19). Doi: 10.3390/jcm11144178

Key clinical point: Golimumab was effective as a second-line anti-tumor necrosis factor-alpha (TNFα) treatment in a real-world setting of patients with psoriatic arthritis (PsA) who failed the first-line anti-TNFα therapy.

Major finding: After 6 months, 31.9% (95% CI 21.4%–44.0%) and 73.8% (95% CI 58.0%–86.1%) of patients with PsA achieved minimal disease activity and a good/moderate response as per the European Alliance of Associations for Rheumatology, respectively, along with significant improvements in disease activity score in 28 joints based on C-reactive protein score (P < .001).

Study details: Findings are from the prospective, observational, real-world study including 194 patients with moderate-to-active rheumatoid arthritis (n = 39), PsA (n = 91), or axial spondyloarthritis (n = 64) who started golimumab after first-line anti-TNFα inhibitor failure.

Disclosures: This study was funded by MSD Italia S.r.l. Two authors declared being employees of MSD Italia, and the other authors reported ties with several sources, including Merck.

Source: D’Angelo S et al. Effectiveness of golimumab as second anti-TNFα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study. J Clin Med. 2022;11(14):4178 (Jul 19). Doi: 10.3390/jcm11144178

Key clinical point: The 3-year bimekizumab treatment was well tolerated and effective in reducing the signs and symptoms of psoriatic arthritis (PsA).

Major finding: By week 152, 89.3% of patients had reported ≥1 treatment-emergent adverse event (TEAE), with serious TEAE being reported by 10.7% of patients. At least 20% improvement in American College of Rheumatology score was maintained by 64.1% of patients at week 152 compared with 72.3% of patients at week 48.

Study details: Findings are 3-year results from the phase 2b BE ACTIVE trial including 206 adults with active PsA who were randomly assigned to receive bimekizumab or placebo for 48 weeks, of which 184 patients were enrolled in the open-label extension phase for a further 104 weeks of treatment.

Disclosures: This study was supported by UCB Pharma. Four authors declared being employees of UCB Pharma and shareholders of UCB Pharma or GlaxoSmithKline. The other authors reported ties with various sources.

Source: Coates LC et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 (Jul 13). Doi: 10.1002/art.42280

Key clinical point: The 3-year bimekizumab treatment was well tolerated and effective in reducing the signs and symptoms of psoriatic arthritis (PsA).

Major finding: By week 152, 89.3% of patients had reported ≥1 treatment-emergent adverse event (TEAE), with serious TEAE being reported by 10.7% of patients. At least 20% improvement in American College of Rheumatology score was maintained by 64.1% of patients at week 152 compared with 72.3% of patients at week 48.

Study details: Findings are 3-year results from the phase 2b BE ACTIVE trial including 206 adults with active PsA who were randomly assigned to receive bimekizumab or placebo for 48 weeks, of which 184 patients were enrolled in the open-label extension phase for a further 104 weeks of treatment.

Disclosures: This study was supported by UCB Pharma. Four authors declared being employees of UCB Pharma and shareholders of UCB Pharma or GlaxoSmithKline. The other authors reported ties with various sources.

Source: Coates LC et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 (Jul 13). Doi: 10.1002/art.42280

Key clinical point: The 3-year bimekizumab treatment was well tolerated and effective in reducing the signs and symptoms of psoriatic arthritis (PsA).

Major finding: By week 152, 89.3% of patients had reported ≥1 treatment-emergent adverse event (TEAE), with serious TEAE being reported by 10.7% of patients. At least 20% improvement in American College of Rheumatology score was maintained by 64.1% of patients at week 152 compared with 72.3% of patients at week 48.

Study details: Findings are 3-year results from the phase 2b BE ACTIVE trial including 206 adults with active PsA who were randomly assigned to receive bimekizumab or placebo for 48 weeks, of which 184 patients were enrolled in the open-label extension phase for a further 104 weeks of treatment.

Disclosures: This study was supported by UCB Pharma. Four authors declared being employees of UCB Pharma and shareholders of UCB Pharma or GlaxoSmithKline. The other authors reported ties with various sources.

Source: Coates LC et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 (Jul 13). Doi: 10.1002/art.42280

Key clinical point: RHOA expression level is associated with clinical features, including Union for International Cancer Control (UICC) stage progression and poorly differentiated status, in patients with gastric cancer.

Major finding: High/positive RHOA expression was significantly associated with UICC stage progression (III-IV vs I-II: odds ratio [OR] 1.37; P  =  .02) and poorly differentiated status (poorly differentiated vs well/moderately differentiated: OR,1.65; P  =  .02).

Study details: This was a meta-analysis of 10 retrospective case-control studies including 1389 patients with gastric cancer, of which 735 were RHOA positive and 654 were RHOA negative.

Disclosures: This study was sponsored by the Basic Science Research Program, through the National Research Foundation of Korea, funded by the Ministry of Education, and the Gachon University Gil Medical Center. The authors declared no conflicts of interest.

Source: Nam S et al. RHOA protein expression correlates with clinical features in gastric cancer: A systematic review and meta-analysis. BMC Cancer. 2022; 22(1):798 (Jul 19). Doi: 10.1186/s12885-022-09904-7

Key clinical point: RHOA expression level is associated with clinical features, including Union for International Cancer Control (UICC) stage progression and poorly differentiated status, in patients with gastric cancer.

Major finding: High/positive RHOA expression was significantly associated with UICC stage progression (III-IV vs I-II: odds ratio [OR] 1.37; P  =  .02) and poorly differentiated status (poorly differentiated vs well/moderately differentiated: OR,1.65; P  =  .02).

Study details: This was a meta-analysis of 10 retrospective case-control studies including 1389 patients with gastric cancer, of which 735 were RHOA positive and 654 were RHOA negative.

Disclosures: This study was sponsored by the Basic Science Research Program, through the National Research Foundation of Korea, funded by the Ministry of Education, and the Gachon University Gil Medical Center. The authors declared no conflicts of interest.

Source: Nam S et al. RHOA protein expression correlates with clinical features in gastric cancer: A systematic review and meta-analysis. BMC Cancer. 2022; 22(1):798 (Jul 19). Doi: 10.1186/s12885-022-09904-7

Key clinical point: RHOA expression level is associated with clinical features, including Union for International Cancer Control (UICC) stage progression and poorly differentiated status, in patients with gastric cancer.

Major finding: High/positive RHOA expression was significantly associated with UICC stage progression (III-IV vs I-II: odds ratio [OR] 1.37; P  =  .02) and poorly differentiated status (poorly differentiated vs well/moderately differentiated: OR,1.65; P  =  .02).

Study details: This was a meta-analysis of 10 retrospective case-control studies including 1389 patients with gastric cancer, of which 735 were RHOA positive and 654 were RHOA negative.

Disclosures: This study was sponsored by the Basic Science Research Program, through the National Research Foundation of Korea, funded by the Ministry of Education, and the Gachon University Gil Medical Center. The authors declared no conflicts of interest.

Source: Nam S et al. RHOA protein expression correlates with clinical features in gastric cancer: A systematic review and meta-analysis. BMC Cancer. 2022; 22(1):798 (Jul 19). Doi: 10.1186/s12885-022-09904-7

Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.

Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P  =  .02) and overall survival (OS; aHR 4.55; P  =  .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P  =  .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P  =  .02 and aHR 6.89; P < .01, respectively).

Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.

Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.

Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6

Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.

Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P  =  .02) and overall survival (OS; aHR 4.55; P  =  .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P  =  .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P  =  .02 and aHR 6.89; P < .01, respectively).

Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.

Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.

Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6

Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.

Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P  =  .02) and overall survival (OS; aHR 4.55; P  =  .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P  =  .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P  =  .02 and aHR 6.89; P < .01, respectively).

Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.

Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.

Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6